Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.

Weiss JM, Robinet M, Aricha R, Cufi P, Villeret B, Lantner F, Shachar I, Fuchs S, Souroujon MC, Berrih-Aknin S, Le Panse R.

Oncotarget. 2016 Feb 16;7(7):7550-62. doi: 10.18632/oncotarget.6885.

2.

Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells.

Aricha R, Reuveni D, Fuchs S, Souroujon MC.

J Autoimmun. 2016 Feb;67:57-64. doi: 10.1016/j.jaut.2015.09.005. Epub 2015 Oct 17.

PMID:
26489998
3.

IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis.

Maurer M, Bougoin S, Feferman T, Frenkian M, Bismuth J, Mouly V, Clairac G, Tzartos S, Fadel E, Eymard B, Fuchs S, Souroujon MC, Berrih-Aknin S.

Acta Neuropathol Commun. 2015 Jan 15;3:1. doi: 10.1186/s40478-014-0179-6.

4.

Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.

Fuchs S, Aricha R, Reuveni D, Souroujon MC.

J Autoimmun. 2014 Nov;54:51-9. doi: 10.1016/j.jaut.2014.06.003. Epub 2014 Jun 24. Review.

PMID:
24970384
5.

Resistance of LPS-activated bone marrow derived macrophages to apoptosis mediated by dexamethasone.

Haim YO, Unger ND, Souroujon MC, Mittelman M, Neumann D.

Sci Rep. 2014 Mar 10;4:4323. doi: 10.1038/srep04323.

6.

Age dependent course of EAE in Aire-/- mice.

Aharoni R, Aricha R, Eilam R, From I, Mizrahi K, Arnon R, Souroujon MC, Fuchs S.

J Neuroimmunol. 2013 Sep 15;262(1-2):27-34. doi: 10.1016/j.jneuroim.2013.06.001. Epub 2013 Jul 9.

PMID:
23849800
7.

Cutting edge in myasthenia gravis.

Berrih-Aknin S, Souroujon MC.

Autoimmun Rev. 2013 Jul;12(9):861-2. doi: 10.1016/j.autrev.2013.03.008. Epub 2013 Mar 25. No abstract available.

PMID:
23535161
8.

Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model.

Gertel-Lapter S, Mizrachi K, Berrih-Aknin S, Fuchs S, Souroujon MC.

Autoimmun Rev. 2013 Jul;12(9):894-903. doi: 10.1016/j.autrev.2013.03.009. Epub 2013 Mar 25. Review.

PMID:
23535156
9.

Experimental myasthenia gravis in Aire-deficient mice: a link between Aire and regulatory T cells.

Aricha R, Feferman T, Berrih-Aknin S, Fuchs S, Souroujon MC.

Ann N Y Acad Sci. 2012 Dec;1275:107-13. doi: 10.1111/j.1749-6632.2012.06843.x. Review.

PMID:
23278585
10.

Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis.

Souroujon MC, Aricha R, Feferman T, Mizrachi K, Reuveni D, Fuchs S.

Ann N Y Acad Sci. 2012 Dec;1274:120-6. doi: 10.1111/j.1749-6632.2012.06844.x.

PMID:
23252906
11.

Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.

Aricha R, Mizrachi K, Fuchs S, Souroujon MC.

J Autoimmun. 2011 Mar;36(2):135-41. doi: 10.1016/j.jaut.2010.12.001. Epub 2010 Dec 30.

PMID:
21193288
12.

The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells.

Aricha R, Feferman T, Scott HS, Souroujon MC, Berrih-Aknin S, Fuchs S.

J Autoimmun. 2011 Feb;36(1):16-24. doi: 10.1016/j.jaut.2010.09.007. Epub 2010 Oct 29.

PMID:
21035305
13.

Development of novel therapies for MG: Studies in animal models.

Souroujon MC, Brenner T, Fuchs S.

Autoimmunity. 2010 Aug;43(5-6):446-60. doi: 10.3109/08916930903518081. Review.

PMID:
20298126
14.

Insertion of an NPVY sequence into the cytosolic domain of the erythropoietin receptor selectively affects erythropoietin-mediated signalling and function.

Liron T, Nahari T, Souroujon MC, Neumann D.

Biochem J. 2010 Mar 29;427(2):305-12. doi: 10.1042/BJ20091951.

PMID:
20136632
15.

Involvement of phosphodiesterases in autoimmune diseases.

Mizrachi K, Aricha R, Feferman T, Kela-Madar N, Mandel I, Paperna T, Miller A, Ben-Nun A, Berrih-Aknin S, Souroujon MC, Fuchs S.

J Neuroimmunol. 2010 Mar 30;220(1-2):43-51. doi: 10.1016/j.jneuroim.2009.12.012. Epub 2010 Jan 25.

PMID:
20100627
16.

Translational neuroimmunology: a joint meeting of the Israel Society of Neuroimmunology and the Italian Neuroimmunology Association. Conference review.

Miller A, Souroujon MC, Aloisi F.

J Neuroimmunol. 2009 Nov 30;216(1-2):4-7. doi: 10.1016/j.jneuroim.2009.08.006. Epub 2009 Sep 19. No abstract available.

PMID:
19767112
17.

Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3.

Feferman T, Aricha R, Mizrachi K, Geron E, Alon R, Souroujon MC, Fuchs S.

J Neuroimmunol. 2009 Apr 30;209(1-2):87-95. doi: 10.1016/j.jneuroim.2009.01.021. Epub 2009 Feb 20.

PMID:
19232748
18.

Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.

Yi HJ, Chae CS, So JS, Tzartos SJ, Souroujon MC, Fuchs S, Im SH.

Mol Immunol. 2008 Nov;46(1):192-201. doi: 10.1016/j.molimm.2008.08.264. Epub 2008 Sep 16.

PMID:
18799218
19.

Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.

Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S.

J Neuroimmunol. 2008 Sep 15;201-202:128-35. doi: 10.1016/j.jneuroim.2008.05.023. Epub 2008 Jul 15. Erratum in: J Neuroimmunol. 2009 Oct 30;215(1-2):129.

PMID:
18632163
20.

Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction.

Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Brenner T, Laub O, Souroujon MC.

Ann N Y Acad Sci. 2008;1132:244-8. doi: 10.1196/annals.1405.032.

PMID:
18567875
21.
22.

Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis.

Aricha R, Feferman T, Fuchs S, Souroujon MC.

J Immunol. 2008 Feb 15;180(4):2132-9.

23.

A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis.

Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, Zhu KY, Brenner T, Laub O, Souroujon MC.

J Neuroimmunol. 2008 Feb;194(1-2):89-96. doi: 10.1016/j.jneuroim.2007.11.020. Epub 2008 Feb 21.

PMID:
18178258
24.

Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction.

Fuchs S, Feferman T, Zhu KY, Meidler R, Margalit R, Wang N, Laub O, Souroujon MC.

Ann N Y Acad Sci. 2007 Sep;1110:550-8.

PMID:
17911471
25.

DNA microarray in search of new drug targets for myasthenia gravis.

Feferman T, Aricha R, Menon R, Souroujon MC, Berrih-Aknin S, Fuchs S.

Ann N Y Acad Sci. 2007 Jun;1107:111-7.

PMID:
17804538
26.

Overexpression of amyloid precursor protein reduces epsilon protein kinase C levels.

Liron T, Seraya CB, Ish-Shalom M, Souroujon MC, Neumann D.

Neuroscience. 2007 Apr 25;146(1):152-9. Epub 2007 Feb 22.

PMID:
17321053
27.

Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms.

Zhu KY, Feferman T, Maiti PK, Souroujon MC, Fuchs S.

J Neuroimmunol. 2006 Jul;176(1-2):187-97. Epub 2006 May 26.

PMID:
16730380
28.

Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor.

Aricha R, Feferman T, Souroujon MC, Fuchs S.

FASEB J. 2006 Feb;20(2):374-6. Epub 2005 Dec 19.

PMID:
16365386
29.

Vaccines against myasthenia gravis.

Berrih-Aknin S, Fuchs S, Souroujon MC.

Expert Opin Biol Ther. 2005 Jul;5(7):983-95. Review.

30.

Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis.

Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC.

J Immunol. 2005 May 1;174(9):5324-31.

31.

Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.

Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S.

J Neuroimmunol. 2004 Jul;152(1-2):112-20.

PMID:
15223243
32.

State-specific monoclonal antibodies identify an intermediate state in epsilon protein kinase C activation.

Souroujon MC, Yao L, Chen H, Endemann G, Khaner H, Geeraert V, Schechtman D, Gordon AS, Diamond I, Mochly-Rosen D.

J Biol Chem. 2004 Apr 23;279(17):17617-24. Epub 2004 Feb 3.

33.

Suppression of myasthenia gravis by antigen-specific mucosal tolerance and modulation of cytokines and costimulatory factors.

Souroujon MC, Maiti PK, Feferman T, Im SH, Raveh L, Fuchs S.

Ann N Y Acad Sci. 2003 Sep;998:533-6.

PMID:
14592924
34.

Epitope spreading to hidden cytoplasmic regions of the acetylcholine receptor in experimental autoimmune myasthenia gravis.

Feferman T, Im SH, Fuchs S, Souroujon MC.

Ann N Y Acad Sci. 2003 Sep;998:388-90. No abstract available.

PMID:
14592902
35.

Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis.

Feferman T, Im SH, Fuchs S, Souroujon MC.

J Neuroimmunol. 2003 Jul;140(1-2):153-8.

PMID:
12864983
36.

A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP.

Maiti PK, Im SH, Souroujon MC, Fuchs S.

Immunol Lett. 2003 Jan 2;85(1):65-70.

PMID:
12505199
37.

Rat interleukin-18 binding protein: cloning, expression, and characterization.

Im SH, Kim SH, Azam T, Venkatesh N, Dinarello CA, Fuchs S, Souroujon MC.

J Interferon Cytokine Res. 2002 Mar;22(3):321-8.

PMID:
12034039
38.

Protective molecular mimicry in experimental myasthenia gravis.

Im SH, Barchan D, Feferman T, Raveh L, Souroujon MC, Fuchs S.

J Neuroimmunol. 2002 May;126(1-2):99-106.

PMID:
12020961
39.

Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.

Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, Fuchs S.

FASEB J. 2001 Oct;15(12):2140-8.

PMID:
11641240
40.
41.
42.

Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.

Im SH, Barchan D, Souroujon MC, Fuchs S.

J Immunol. 2000 Oct 1;165(7):3599-605.

43.
44.

Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation.

Dorn GW 2nd, Souroujon MC, Liron T, Chen CH, Gray MO, Zhou HZ, Csukai M, Wu G, Lorenz JN, Mochly-Rosen D.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12798-803.

45.
46.

Peptide modulators of protein-protein interactions in intracellular signaling.

Souroujon MC, Mochly-Rosen D.

Nat Biotechnol. 1998 Oct;16(10):919-24. Review.

PMID:
9788346
47.

Modulation of experimental autoimmune myasthenia gravis by recombinant fragments of the human acetylcholine receptor.

Souroujon MC, Barchan D, Fuchs S.

Ann N Y Acad Sci. 1998 May 13;841:572-5. No abstract available.

PMID:
9668298
48.
49.

Identification of epitopes within a highly immunogenic region of acetylcholine receptor by a phage epitope library.

Barchan D, Balass M, Souroujon MC, Katchalski-Katzir E, Fuchs S.

J Immunol. 1995 Nov 1;155(9):4264-9.

PMID:
7594584
50.

Acetylcholine receptor and myogenic factor gene expression in Torpedo embryonic development.

Asher O, Fuchs S, Souroujon MC.

Neuroreport. 1994 Aug 15;5(13):1581-4.

PMID:
7819524

Supplemental Content

Loading ...
Support Center